C2 has worse PSA, rPFS, and OS in two multicenter phase II trials of androgen receptor signaling inhibitors. Kaplan-Meier plot of (A) OS, (B) PSA PFS, and (C) rPFS for patients in C2 compared with C1 in patient treated with enzalutamide or abiraterone acetate. C1, cluster 1; C2, cluster 2; HR, hazard ratio; NR, not reached; OS, overall survival; PFS, progression-free survival; PSA, prostate-specific antigen; rPFS, radiographic progression-free survival.